Phosphatidylinositol 3-kinase signaling and immune regulation: insights into disease pathogenesis and clinical implications

References

• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317–330.
   PubMed Web of Science ®Google Scholar
• Baracho GV, Miletic AV, Omori SA, et al. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011;23(2):178–183.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;67:481–507.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang Y, McIlroy J, et al. Regulation of the p85/p110 phosphatidylinositol 3ʹ-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol. 1998;18(3):1379–1387.
   PubMed Web of Science ®Google Scholar
• Luo J, Cantley LC. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it’s implication in cancer. Cell Cycle. 2005;4(10):1309–1312.
   PubMed Web of Science ®Google Scholar
• Chantry D, Vojtek A, Kashishian A, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem. 1997;272(31):19236–19241.
   PubMed Web of Science ®Google Scholar
• Koyasu S. The role of PI3K in immune cells. Nat Immunol. 2003;4(4):313–319.
   PubMed Web of Science ®Google Scholar
• Okada T, Maeda A, Iwamatsu A, et al. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity. 2000;13(6):817–827.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
   PubMed Web of Science ®Google Scholar
• Wang X, Proud CG. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda). 2006;21:362–369.
   PubMed Web of Science ®Google Scholar
• Browne CD, Del Nagro CJ, Cato MH, et al. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity. 2009;31(5):749–760.
   PubMed Web of Science ®Google Scholar
• Lau A, Avery DT, Jackson K, et al. Activated PI3Kdelta breaches multiple B cell tolerance checkpoints and causes autoantibody production. J Exp Med. 2020; 217(2).
   Web of Science ®Google Scholar
• Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9(6):667–676.
   PubMed Web of Science ®Google Scholar
• Miletic AV, Anzelon-Mills AN, Mills DM, et al. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. J Exp Med. 2010;207(11):2407–2420.
   PubMed Web of Science ®Google Scholar
• Angulo I, Vadas O, Garcon F, et al. Phosphoinositide 3-kinase gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866–871.
   PubMed Web of Science ®Google Scholar
• Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1): 88–97.
   PubMed Web of Science ®Google Scholar
• Deau MC, Heurtier L, Frange P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124(9): 3923–3928.
   PubMed Web of Science ®Google Scholar
• Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210–218 e9.
   PubMed Web of Science ®Google Scholar
• Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2): 597–606 e4.
   PubMed Web of Science ®Google Scholar
• Leslie NR, Dixon MJ, Schenning M, et al. Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. Adv Biol Regul. 2012;52(1):205–213.
   PubMedGoogle Scholar
• Leslie NR, Downes CP. PTEN: the down side of PI 3-kinase signalling. Cell Signal. 2002;14(4):285–295.
   PubMed Web of Science ®Google Scholar
• Milella M, Falcone I, Conciatori F, et al. PTEN: multiple Functions in Human Malignant Tumors. Front Oncol. 2015;5:24.
   PubMed Web of Science ®Google Scholar
• Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7(3):507–515.
   PubMed Web of Science ®Google Scholar
• Tsujita Y, Mitsui-Sekinaka K, Imai K, et al. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase delta syndrome-like immunodeficiency. J Allergy Clin Immunol. 2016;138(6):1672–1680 e10.
   PubMed Web of Science ®Google Scholar
• Driessen GJ, IJspeert H, Wentink M, et al. Increased PI3K/Akt activity and deregulated humoral immune response in human PTEN deficiency. J Allergy Clin Immunol. 2016;138(6): 1744–1747 e5.
   PubMed Web of Science ®Google Scholar
• Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol. 2002;22(24):8580–8591.
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002;196(6):753–763.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002;297(5583):1031–1034.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Mauvais-Jarvis F, Pollard DA, et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet. 2000;26(3):379–382.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Snapper SB, Yballe CM, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science. 1999;283(5400):393–397.
   PubMed Web of Science ®Google Scholar
• Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature. 1995;376(6538):352–355.
   PubMed Web of Science ®Google Scholar
• Engel P, Zhou L-J, Ord DC, et al. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3(1):39–50.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Takeda K, Inaba M, et al. Cutting edge: essential role of phospholipase C-gamma 2 in B cell development and function. J Immunol. 2000;165(4):1738–1742.
   PubMed Web of Science ®Google Scholar
• Khan WN, Alt FW, Gerstein RM, et al. Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3(3):283–299.
   PubMed Web of Science ®Google Scholar
• Ueki K, Fruman DA, Brachmann SM, et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol. 2002;22(3):965–977.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Ueki K, Fruman DA, et al. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest. 2002;109(1):141–149.
   PubMed Web of Science ®Google Scholar
• Preite S, Gomez‐Rodriguez J, Cannons JL, et al. T and B-cell signaling in activated PI3K delta syndrome: from immunodeficiency to autoimmunity. Immunol Rev. 2019;291(1):154–173.
   PubMed Web of Science ®Google Scholar
• Tangye SG, Bier J, Lau A, et al. Immune dysregulation and disease pathogenesis due to activating mutations in PIK3CD-the Goldilocks’ Effect. J Clin Immunol. 2019;39(2):148–158.
   PubMed Web of Science ®Google Scholar
• Lucas CL, Zhang Y, Venida A, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211(13):2537–2547.
   PubMed Web of Science ®Google Scholar
• Carpier JM, Lucas CL. Epstein-barr virus susceptibility in activated PI3Kdelta Syndrome (APDS) Immunodeficiency. Front Immunol. 2017;8:2005.
   PubMed Web of Science ®Google Scholar
• !!! INVALID CITATION !!! {Coulter, 2017 #19;Lucas, 2014 #55;Angulo, 2013 #2;Crank, 2014 #22;Hartman, 2015 #660;Chiriaco, 2017 #659;Takeda, 2017 #661}.
   Google Scholar
• Petrovski S, Parrott RE, Roberts JL, et al. Dominant Splice Site Mutations in PIK3R1 Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature. J Clin Immunol. 2016;36(5):462–471.
   PubMed Web of Science ®Google Scholar
• Lougaris V, Faletra F, Lanzi G, et al. Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype. Clin Immunol. 2015;159(1):33–36.
   PubMed Web of Science ®Google Scholar
• Olbrich P, Lorenz M, Cura Daball P, et al. Activated PI3Kdelta syndrome type 2: two patients, a novel mutation, and review of the literature. Pediatr Allergy Immunol. 2016;27(6):640–644.
   PubMed Web of Science ®Google Scholar
• Bravo Garcia-Morato M, García-Miñaúr S, Molina Garicano J, et al. Mutations in PIK3R1 can lead to APDS2, SHORT syndrome or a combination of the two. Clin Immunol. 2017;179:77–80.
   PubMed Web of Science ®Google Scholar
• Kuhlen M, Hönscheid A, Loizou L, et al. De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly. Clin Immunol. 2016;162:27–30.
   PubMed Web of Science ®Google Scholar
• Ramirez L, Tamayo W, Ale H. APDS2 and SHORT Syndrome in a Teenager with PIK3R1 Pathogenic Variant. J Clin Immunol. 2020;40:1020–1025.
   PubMedGoogle Scholar
• Dyment DA, Smith A, Alcantara D, et al. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet. 2013;93(1):158–166.
   PubMed Web of Science ®Google Scholar
• Chudasama KK, Winnay J, Johansson S, et al. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum Genet. 2013;93(1):150–157.
   PubMed Web of Science ®Google Scholar
• Thauvin-Robinet C, Auclair M, Duplomb L, et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet. 2013;93(1):141–149.
   PubMed Web of Science ®Google Scholar
• Avery DT, Kane A, Nguyen T, et al. Germline-activating mutations in PIK3CD compromise B cell development and function. J Exp Med. 2018;215(8):2073–2095.
   PubMed Web of Science ®Google Scholar
• Dulau Florea AE, Braylan RC, Schafernak KT, et al. Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD. J Allergy Clin Immunol. 2017;139(3): 1032–1035 e6.
   PubMed Web of Science ®Google Scholar
• Preite S, Cannons JL, Radtke AJ, et al. Hyperactivated PI3Kdelta promotes self and commensal reactivity at the expense of optimal humoral immunity. Nat Immunol. 2018;19(9):986–1000.
   PubMed Web of Science ®Google Scholar
• Stark AK, Chandra A, Chakraborty K, et al. PI3Kdelta hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. Nat Commun. 2018;9(1):3174.
   PubMedGoogle Scholar
• Bier J, Rao G, Payne K, et al. Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4(+) T cells. J Allergy Clin Immunol. 2019;144(1): 236–253.
   PubMed Web of Science ®Google Scholar
• Ueno H. T follicular helper cells in human autoimmunity. Curr Opin Immunol. 2016;43:24–31.
   PubMed Web of Science ®Google Scholar
• Edwards ESJ, Bier J, Cole TS, et al. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity. J Allergy Clin Immunol. 2019143: 276-291.e6. DOI: https://doi.org/10.1016/j.jaci.2018.04.030.
   Google Scholar
• Wentink MWJ, Mueller YM, Dalm VASH, et al. Exhaustion of the CD8(+) T cell compartment in patients with mutations in phosphoinositide 3-kinase delta. Front Immunol. 2018;9:446.
   PubMed Web of Science ®Google Scholar
• Cannons JL, Preite S, Kapnick SM, et al. Genetic defects in phosphoinositide 3-kinase delta influence CD8(+) T cell survival, differentiation, and function. Front Immunol. 2018;9:1758.
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia R, Vargas-Hernández A, Chinn IK, et al. Mutations in PI3K110delta cause impaired natural killer cell function partially rescued by rapamycin treatment. J Allergy Clin Immunol. 2018;142(2):605–617 e7.
   PubMed Web of Science ®Google Scholar
• Preite S, Huang B, Cannons JL, et al. PI3K orchestrates T follicular helper cell differentiation in a context dependent manner: implications for autoimmunity. Front Immunol. 2018;9:3079.
   PubMed Web of Science ®Google Scholar
• Crank MC, Grossman JK, Moir S, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34(3):272–276.
   PubMed Web of Science ®Google Scholar
• Elgizouli M, Lowe DM, Speckmann C, et al. Activating PI3Kdelta mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol. 2016;183(2):221–229.
   PubMed Web of Science ®Google Scholar
• Michalovich D, Nejentsev S. Activated PI3 kinase delta syndrome: from genetics to therapy. Front Immunol. 2018;9:369.
   PubMed Web of Science ®Google Scholar
• Nademi Z, Slatter MA, Dvorak CC, et al. Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. J Allergy Clin Immunol. 2017;139(3):1046–1049.
   PubMed Web of Science ®Google Scholar
• Okano T, Imai K, Tsujita Y, et al. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase delta syndrome type 1. J Allergy Clin Immunol. 2019;143(1):266–275.
   PubMed Web of Science ®Google Scholar
• Dimitrova D, Nademi Z, Maccari ME, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2021.
   PubMedGoogle Scholar
• Notarangelo LD. Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase delta syndrome: who, when, and how? J Allergy Clin Immunol. 2019;143(1):91–93.
   PubMed Web of Science ®Google Scholar
• Castagnoli R, Delmonte OM, Calzoni E, et al. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019;7:295.
   PubMed Web of Science ®Google Scholar
• Rousso SZ, Shamriz O, Zilkha A, et al. Hematopoietic stem cell transplantations for primary immune deficiencies: 3 decades of experience from a tertiary medical center. J Pediatr Hematol Oncol. 2015;37(5):e295–300.
   PubMed Web of Science ®Google Scholar
• Morris EC, Albert MH. Allogeneic HSCT in adolescents and young adults with primary immunodeficiencies. Front Pediatr. 2019;7:437.
   PubMed Web of Science ®Google Scholar
• Wentink M, Dalm V, Lankester AC, et al. Genetic defects in PI3Kdelta affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections. Clin Immunol. 2017;176:77–86.
   PubMed Web of Science ®Google Scholar
• Rae W, Ramakrishnan KA, Gao Y, et al. Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase delta syndrome. Clin Immunol. 2016;171:38–40.
   PubMed Web of Science ®Google Scholar
• Maccari ME, Abolhassani H, Aghamohammadi A, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase delta syndrome: the European society for immunodeficiencies-activated phosphoinositide 3-kinase delta syndrome registry. Front Immunol. 2018;9:543.
   PubMed Web of Science ®Google Scholar
• Goto F, Uchiyama T, Nakazawa Y, et al. Persistent impairment of T-cell regeneration in a patient with activated PI3K delta Syndrome. J Clin Immunol. 2017;37(4):347–350.
   PubMed Web of Science ®Google Scholar
• Rao VK, et al. Effective ‘Activated PI3Kdelta Syndrome’-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood. 2017;130:2307-2316. DOI: https://doi.org/10.1182/blood-2017-08-801191.
   Google Scholar
• Coulter TI, Cant AJ. The treatment of activated PI3Kdelta Syndrome. Front Immunol. 2018;9:2043.
   PubMed Web of Science ®Google Scholar
• Conley ME, Dobbs AK, Quintana AM, et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85alpha subunit of PI3K. J Exp Med. 2012;209(3):463–470.
   PubMed Web of Science ®Google Scholar
• Tang P, Upton JEM, Barton-Forbes MA, et al. Autosomal recessive agammaglobulinemia due to a homozygous mutation in PIK3R1. J Clin Immunol. 2018;38(1):88–95.
   PubMed Web of Science ®Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–728.
   PubMed Web of Science ®Google Scholar
• Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol. 2000;19(2):183–204.
   PubMed Web of Science ®Google Scholar
• Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85(4):193–202.
   PubMed Web of Science ®Google Scholar
• Sogkas G, Fedchenko M, Dhingra A, et al. Primary immunodeficiency disorder caused by phosphoinositide 3-kinase delta deficiency. J Allergy Clin Immunol. 2018;142(5):1650–1653 e2.
   PubMed Web of Science ®Google Scholar
• Sharfe N, Karanxha A, Dadi H, et al. Dual loss of p110delta PI3-kinase and SKAP (KNSTRN) expression leads to combined immunodeficiency and multisystem syndromic features. J Allergy Clin Immunol. 2018;142(2):618–629.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Bainter W, Johnson JL, et al. Human primary immunodeficiency caused by expression of a kinase-dead p110delta mutant. J Allergy Clin Immunol. 2019;143:797-799.e2. DOI: https://doi.org/10.1016/j.jaci.2018.10.005.
   Google Scholar
• Rodriguez R, Fournier B, Cordeiro DJ, et al. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. J Exp Med. 2019;216(12):2800–2818.
   PubMed Web of Science ®Google Scholar
• Swan DJ, Aschenbrenner D, Lamb CA, et al. Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase δ. Haematologica. 2019;104(10):e483–e486.
   PubMed Web of Science ®Google Scholar
• Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A. 1989;86(6):1963–1967.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 2014;47(3):122–129.
   PubMed Web of Science ®Google Scholar
• Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186(1):47–55.
   PubMed Web of Science ®Google Scholar
• Dobyns WB, Mirzaa GM. Megalencephaly syndromes associated with mutations of core components of the PI3K-AKT-MTOR pathway: PIK3CA, PIK3R2, AKT3, and MTOR. Am J Med Genet C Semin Med Genet. 2019;181(4):582–590.
   PubMed Web of Science ®Google Scholar
• Gordo G, Tenorio J, Arias P, et al. mTOR mutations in Smith-Kingsmore syndrome: four additional patients and a review. Clin Genet. 2018;93(4):762–775.
   PubMed Web of Science ®Google Scholar
• Browning MJ, Chandra A, Carbonaro V, et al. Cowden’s syndrome with immunodeficiency. J Med Genet. 2015;52(12):856–859.
   PubMed Web of Science ®Google Scholar
• Eissing M, Ripken L, Schreibelt G, et al. PTEN hamartoma tumor syndrome and immune dysregulation. Transl Oncol. 2019;12(2):361–367.
   PubMed Web of Science ®Google Scholar
• Emerson JS, Lee EY, Berglund LJ. Treatment of immune dysregulation due to a PTEN Variant with Sirolimus. J Clin Immunol. 2021.
   PubMed Web of Science ®Google Scholar
• Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008;5(6):357–361.
   PubMedGoogle Scholar
• Komiya T, Blumenthal GM, DeChowdhury R, et al. A pilot study of sirolimus in subjects with cowden syndrome or other syndromes characterized by germline mutations in PTEN. Oncologist. 2019;24(12):1510–e1265.
   PubMed Web of Science ®Google Scholar
• Cahn A, Hamblin JN, Begg M, et al. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kdelta inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther. 2017;46:69–77.
   PubMed Web of Science ®Google Scholar